Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aim: 6-month multicentre, observational, open study evaluated the efficacy and tolerability of the new generation antipsychotic drug amisulpride in patients with acute schizophrenia.
Method: 99 patients were included in the study, 72 (72%) completed the 6-month observation.
Results: Marked improvement in CGI after 6 months of treatment was observed in 56 (56%) patients. Therapy with amisulpride reduced both positive (20% reduction of positive symptoms in the PANSS positive subscale in 78%) and negative symptoms (20% reduction of negative symptoms in the PANSS negative subscale in 77%).
Conclusion: Amisulpride was well tolerated, adverse events responsible for premature withdrawal from the study were observed only in 6% patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Generic Intravenous Amisulpride (QLG2069) for the Prevention of Postoperative Nausea and Vomiting in Adults: A Phase III, Multicenter, Randomized, Placebo-Controlled Study.
Drug Des Devel Ther
September 2025
Department of Anesthesiology, Peking University People's Hospital, Beijing, People's Republic of China.
Background: The dopamine D2/D3 antagonist amisulpride has demonstrated its superiority and efficacy in prophylaxis of postoperative nausea and vomiting (PONV). Given the branded intravenous amisulpride (Barhemsys) has not been approved in China, there is unmet clinical need for amisulpride. Our primary objective was to ascertain the efficacy and safety of the generic intravenous amisulpride (QLG2069) in the prophylaxis of PONV.
View Article and Find Full Text PDFSexual dysfunctions related to use of antipsychotics: A protocol for a systematic review and meta-analysis.
PLoS One
August 2025
Lentis Research, Lentis Mental Health Institute, Groningen, The Netherlands.
Introduction: Sexual dysfunctions are a challenging side effect associated with antipsychotic treatment. This protocol outlines a systematic review and meta-analysis to assess the prevalence of overall sexual dysfunction, as well as the specific phases of sexual function affected by antipsychotic medications. Additionally, the analysis will explore the relationship between prolactin levels and sexual dysfunction.
View Article and Find Full Text PDFPatterns of Serum Prolactin Elevation Associated with Nine Second-Generation Antipsychotics in a Large Cohort of Patients with Schizophrenia.
CNS Drugs
August 2025
Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, No.600 Wan Ping South Road, Shanghai, 200030, China.
Background: Prolactin elevation associated with antipsychotic use significantly affects medication adherence and long-term treatment outcomes in patients with schizophrenia. The currently available data are insufficient to guide the monitoring and management of elevated prolactin levels in patients on antipsychotic medications. This study aimed to explore the patterns of prolactin level elevation associated with nine second-generation antipsychotics (SGAs) in a real-world setting and compare the associated risks.
View Article and Find Full Text PDFCorrelation Between Serum Amisulpride Concentration, Therapeutic Efficacy, and Glycolipid Metabolism in the Treatment of Adult Female Schizophrenia.
Actas Esp Psiquiatr
August 2025
Department of Laboratory, The Third People's Hospital of Yongkang, 321300 Yongkang, Zhejiang, China.
Background: Amisulpride is a novel atypical antipsychotic (AAP) with slower absorption, metabolism, and excretion in females, potentially leading to elevated plasma concentrations. This study aimed to explore the correlation between serum amisulpride levels and therapeutic efficacy, glycolipid metabolism and side effects in adult female patients with schizophrenia (SCH).
Methods: A retrospective study was conducted involving 122 adult female SCH patients admitted to the Third People's Hospital of Yongkang between January 2020 and January 2022.
Strategies for Switching between Oral Postsynaptic Antidopaminergic Antipsychotics in Patients with Schizophrenia: A Systematic Review.
CNS Drugs
October 2025
Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, 75-59 263rd St, Glen Oaks, NY, 11004, USA.
Background: Antipsychotic switching is common in the treatment of schizophrenia. Pharmacokinetic and pharmacodynamic properties of antipsychotics can inform switch strategies, as switching from shorter to longer half-life antipsychotics and switching from more antagonistic to less antagonistic or partial agonist agents at dopaminergic, histaminergic, and cholinergic receptors can lead to withdrawal or rebound symptoms, potentially complicating switch results. This systematic literature review of studies investigated switching strategies between oral antipsychotics.
View Article and Find Full Text PDF